{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:33:42Z","timestamp":1769150022391,"version":"3.49.0"},"reference-count":16,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2019]]},"abstract":"<b><i>Introduction:<\/i><\/b> Insulin degludec (IDeg) is the longest-acting basal insulin available. Whether IDeg compared to shorter-acting basal insulins like insulin glargine U100 (IGlarU100) reduces the rate of diabetic ketoacidosis (DKA) in adolescents with type 1 diabetes is unknown. <b><i>Objective:<\/i><\/b> We hypothesized that adolescents with type 1 diabetes would have lower DKA rates and mean hemoglobin A1c (HbA1c) when using IDeg as compared to IGlarU100. <b><i>Methods:<\/i><\/b> To avoid selection bias, we used self-control case series methodology. Adolescents with type 1 diabetes treated for DKA from January 2015 through December 2018 who switched basal insulin from IGlarU100 to IDeg were eligible for analysis. Thirty-five patients were included, each acting as their own control. Mean HbA1c and DKA rate for the 12 months prior to and after switching to IDeg were compared. <b><i>Results:<\/i><\/b> Mean HbA1c prior to and after switching to IDeg was unchanged (97 \u00b1 20 vs. 97 \u00b1 21 mmol\/mol [11.0 \u00b1 1.8 vs. 11.0 \u00b1 1.9%]). Median DKA rate (admissions\/year) while on IGlar\u00adU100 was 1 with an interquartile range (IQR) of 1\u20132. After switching to IDeg, median DKA admission rate remained 1, however the IQR decreased to 0\u20131 (one-sided <i>p<\/i> value 0.0004). Median change in DKA rate was 1 fewer admission per year, with a maximum reduction of 3 admissions. Higher baseline rates of DKA increased the odds of a patient reducing his\/her DKA rate by 1 admission per year or more. <b><i>Conclusions:<\/i><\/b> Using IDeg for basal insulin in adolescent patients may decrease the rate of DKA relative to IGlarU100 despite no improvement in HbA1c and may be cost-effective.<\/jats:p>","DOI":"10.1159\/000504707","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T22:00:33Z","timestamp":1576879233000},"page":"179-185","source":"Crossref","is-referenced-by-count":8,"title":["Insulin Degludec in Adolescents with Type 1 Diabetes: Is Newer Better? \u2013 A Retrospective Self-Control Case Series in Adolescents with a History of Diabetic Ketoacidosis"],"prefix":"10.1159","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-2000","authenticated-orcid":false,"given":"Jessica","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary\u00a0Lauren","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0359"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70190-3"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.19.2511"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0780"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0446-7"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2249"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1058779"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3249"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817731422"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1925"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0400-x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00462"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12821"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0294"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2990"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:14:02Z","timestamp":1745424842000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000504707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,2,13]]}},"URL":"https:\/\/doi.org\/10.1159\/000504707","archive":["Portico"],"relation":{},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"value":"1663-2818","type":"print"},{"value":"1663-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}